Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECTOR: Point of Care Randomisation Feasibility Study
NCT05149820Phase 4Unknown
- Sponsor
- University College London
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of magnesium in Atrial fibrillation (AFib) (4 arms), sponsored by University College London. Primary endpoint: Effectiveness of Electronic Point of Care Randomisation Prompts. Status: unknown.
02
Drugs
magnesium
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05149820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149820.